{"prompt": "['2016N277425_02', 'CONFIDENTIAL', '2018N377698_0', '201749', '4.6.1.', 'Risk Assessment', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Investigational Product (IP) [UMEC/VI]', 'Severe milk protein allergy', 'Anoro contains Lactose monohydrate (which contains milk', 'Exclusion criteria have been set for subjects with milk', 'protein) as an excipient.', 'protein allergy.', 'Cardiovascular effects such as cardiac arrhythmias e.g.', 'Class effects associated with LABAs and LAMA containing', 'Exclusion criteria have been set for subjects with', 'supraventricular tachycardia and extrasystoles.', 'therapy. The clinical significance of these arrhythmias is', 'uncontrolled or severe cardiovascular disease according to', 'unknown. Clinical experience with UMEC/VI to date in', \"the principal investigation's (PI) opinion where the potential\", 'completed studies did not show any association with major', 'risk may outweigh the benefit. The PI should also', 'cardiovascular events.', 'determine the clinical significance of abnormal ECG', 'findings at screening and exclude subjects who would be', 'Data available in the product label for UMEC/VI', 'at undue risk by participating in the trial. Patients with the', 'following abnormalities will be excluded from participation:', 'atrial fibrillation with rapid ventricular rate >120bpm,', 'sustained or nonsustained ventricular tachycardia, or', 'second degree heart block Mobitz type Il or third degree', 'heart block (unless pacemaker or defibrillator had been', 'inserted).', 'Beta agonists and risk of asthma-related death', 'Long-acting beta agonists such as vilanterol when used', 'Subjects with a current diagnosis of asthma are excluded', 'alone may increase the risk of asthma-related death. A', 'from participation in the study.', 'placebo-controlled trial with another LABA (salmeterol)', 'showed an increase in asthma-related deaths in subjects', 'receiving salmeterol. This finding with salmeterol is', 'considered a class effect of all LABAs, including vilanterol.', 'Data are not available to determine whether the rate of death', 'in patients with COPD is increased by LABA.', 'Paradoxical bronchospasm', 'As with other inhaled medicines, UMEC/VI can produce', 'If paradoxical bronchospasm occurs following dosing with', 'paradoxical bronchospasm which may be life threatening.', 'UMEC/VI, this treatment should be discontinued', 'immediately and alternative therapy should be instituted.', 'Use in patients with narrow-angle glaucoma or urinary', 'No association has been found to date, in completed studies', 'Exclusion criterion states that subjects with medical', 'retention', 'with UMEC/VI or UMEC monotherapy, on glaucoma or', 'conditions such as narrow-angle glaucoma, prostatic', 'urinary retention. However, glaucoma or urinary retention', 'hypertrophy, or bladder neck obstruction should only be', '21']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_0', '201749', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'have been observed with other antimuscarinic agents, and', 'included if, in the opinion of the principal investigator, the', 'could potentially be due to the pharmacology.', 'benefit outweighs the risk.', 'Use of beta blockers', 'Beta-adrenergic blockers may weaken or antagonize the', 'The study permitted medications and non drug therapies', 'effect of beta2-agonists such as vilanterol.', 'section states that concomitant administration with beta-', \"blockers is only permitted if, in the Investigator's opinion,\", 'the likely benefit outweighs the potential risk.', 'Pregnancy', 'There is no experience to date of pregnancy during the use', 'The study inclusion criteria ensures that female subjects of', 'of UMEC/VI.', 'child bearing potential must have a negative pregnancy', 'test at screening, and agree to a reliable contraceptive', 'method, used consistently and correctly (i.e. in accordance', 'with the approved product label and the instructions of the', 'physician for the duration of the study) Exclusion criteria', 'include Pregnancy: Women who are pregnant or lactating', 'or are planning on becoming pregnant during the study.', 'Severe hepatic impairment', 'UMEC/VI has not been studied in severe hepatic impairment.', 'Exclusion criterion states that subjects severe hepatic', 'impairment should only be included if, in the opinion of the', 'study physician, the benefit outweighs the risk.', 'Investigational product (IP) [UMEC]', 'Cardiovascular effects such as cardiac arrhythmia, e.g.', 'A potential class effect associated', 'Screening electrocardiogram (ECG) criteria to exclude', 'atrial fibrillation and tachycardia', 'with anti-muscarinic therapies. Data available to date in the', 'subjects potentially at risk', 'IB for UMEC [GlaxoSmithKline Document Number', 'RM2006/00835/09', 'Narrow-angle glaucoma, urinary retention', 'A class effect associated with anti-muscarinic therapies.', 'Exclusion criterion states that subjects with medical', 'Data available in the IB for UMEC [GlaxoSmithKline', 'conditions such as narrow-angle glaucoma, prostatic', 'Document Number RM2006/00835/09', 'hypertrophy, or bladder neck obstruction should only be', 'included if, in the opinion of the study physician, the benefit', 'outweighs the risk.', 'Paradoxical bronchospasm that may be life threatening', 'Known effect associated with inhalation therapy', 'A short-acting inhaled bronchodilator', '(albuterol/salbutamol) will be provided for use as needed', 'throughout the study. The investigators will be instructed to', \"assess subject's condition to determine their eligibility to\", '22']\n\n###\n\n", "completion": "END"}